Yeah, but that's still crack talk. Too many other possibilities which are cheaper and easier to manufacture and administer are coming in to play. They already have a manufacturing process which won't take a long time to ramp up either.
Should the numbers be good with the long tail, this doesn't get taken out for more than $15. To many shares here for the price to go too much higher than that if it even gets there.
Even if this FDA approved, the shelf life of this being 1L treatment alone is short due to the requirement of tumor samples and personalize treatments. There are other drugs already being trialed that don't require any of that that could perform as well
News 
Market Data 
Discover 
AI
